{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-060693","form_type":"8-K","ticker":"PEPG","cik":"0001835597","company_name":"PepGen Inc.","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.894699+00:00","generated_at":"2026-06-08T10:41:16.624994+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"PepGen Q3 2023 net loss $23.3M; cash $129.5M; FDA clears FREEDOM-DM1 study in US","bullets":["Net loss of $23.3M for Q3 2023, vs $18.6M in Q3 2022; R&D expenses $20.5M.","Cash and cash equivalents $129.5M as of Sept 30, 2023; runway expected into 2025.","FDA lifted clinical hold on FREEDOM-DM1 Phase 1 study; target doses 5, 10, 20 mg/kg.","FDA granted Orphan Drug Designation to PGN-EDODM1 for myotonic dystrophy type 1.","Anticipates proof-of-concept data from CONNECT1-EDO51 study in mid-2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-060693","json":"https://secwatch.observer/filing/0000950170-23-060693.json","markdown":"https://secwatch.observer/filing/0000950170-23-060693.md","text":"https://secwatch.observer/filing/0000950170-23-060693.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835597/000095017023060693/0000950170-23-060693-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835597/000095017023060693/pepg-20231108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T10:41:16.624994+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0aed539d59364f8167306e536a26f40b4510d40a","claim":"PepGen Inc. reported the third quarter ended September 30, 2023 results: net income Net loss was $23.3 million.","evidence_excerpt":"PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the third quarter ended September 30, 2023 and highlighted recent corporate developments.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1835597/000095017023060693/0000950170-23-060693-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Net income","value":"Net loss was $23.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}